{"id":"W2107806473","doi":"10.1016/j.eururo.2012.10.048","title":"Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder","year":2012,"lang":"en","type":"article","venue":"European Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":356,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Astellas Pharma Canada; Pfizer; Eli Lilly and Company","keywords":"Mirabegron; Tolterodine; Medicine; Overactive bladder; Tolerability; Placebo; Urology; Adverse effect; Internal medicine; Discontinuation; Agonist; Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002198667,0.001928089,0.006278798,0.0006939073,0.001117334,0.001495046,0.001555581,0.002716642,0.01008188],"category_scores_gemma":[0.002265637,0.001348215,0.002128437,0.0007037702,0.002528759,0.001726099,0.0005562116,0.004389441,0.001720271],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001072826,"about_ca_system_score_gemma":0.002261505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001868273,"about_ca_topic_score_gemma":0.003885816,"domain_scores_codex":[0.9990873,0.0004079035,0.00006388836,0.0001962212,0.00007306076,0.0001716451],"domain_scores_gemma":[0.9981009,0.0004899807,0.0003347917,0.0002354902,0.0001396797,0.0006991292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9861271,0.007143316,0.000161779,0.0002003925,0.0003231265,0.00001510051,0.00002863519,0.0001096135,0.00160433,0.00004265882,0.0003322326,0.003911712],"study_design_scores_gemma":[0.9672491,0.03132278,0.0006961991,0.00001062049,0.0001300318,0.0000101137,0.000008105651,0.00015401,0.0001686997,0.00006036644,0.0001802192,0.000009706248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784012,0.003368091,0.001986967,0.0008289921,0.000837438,0.009577173,0.002151621,0.0004664344,0.002382067],"genre_scores_gemma":[0.9694898,0.002125698,0.004215227,0.002202281,0.0007789239,0.01468391,0.001734353,0.00009551283,0.004674306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01008188,"threshold_uncertainty_score":0.03372729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06821404398549276,"score_gpt":0.3772788177020855,"score_spread":0.3090647737165927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}